資訊工程學系Lin, Fang-YuFang-YuLinYUFENG JANE TSENG2018-09-102018-09-10201115499596http://www.scopus.com/inward/record.url?eid=2-s2.0-79960712148&partnerID=MN8TOARShttp://scholars.lib.ntu.edu.tw/handle/123456789/362625In this work, we describe a structure-based de novo optimization process, called "LeadOp" (short for lead optimization), that decomposes a compound into fragments of different molecular components either by chemical or user-defined rules. Each fragment is evaluated through a predocked fragment database that ranks fragments according to specific fragment-receptor binding interactions, replacing fragments that contribution the least to binding and finally reassembling the fragments to form a new ligand. The fundamental idea is to replace "bad" fragments of a ligand with "good" fragments while leaving the core of the ligand intact, thus improving the compound's activity. The molecular fragments were selected from a collection of 27 417 conformers that are the fragments of compounds in the DrugBank database. The collection of molecular fragments are docked to the target's binding site and evaluated using group efficiency (calculated binding affinity divided by the number of heavy atoms), and the "strongest" binder is selected. The LeadOp method was tested with two biomolecular systems: mutant B-Raf kinase and human 5-lipoxygenase. The LeadOp methodology was able to optimize the query molecules and systematically developed improved analogs for each of our example systems. © 2011 American Chemical Society.4943603 bytesapplication/pdfBinding energy; Binding sites; Database systems; Ligands; Binding affinities; Biomolecular system; Group efficiency; Lead optimization; Molecular components; Molecular fragments; Receptor binding; Structure-based; Query processing; enzyme inhibitor; lipoxygenase inhibitor; peptide fragment; article; binding site; chemical structure; chemistry; human; hydrogen bond; IC 50; molecular library; quantitative structure activity relation; thermodynamics; Binding Sites; Enzyme Inhibitors; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Lipoxygenase Inhibitors; Models, Molecular; Molecular Structure; Peptide Fragments; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Thermodynamicsjournal article10.1021/ci200136j216273272-s2.0-79960712148